Abstract: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.

Abstract: The present invention provides solid forms of the compound of formula 1 and pharmaceutical uses thereof.

Abstract: The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Abstract: A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.

Abstract: Devices and methods are disclosed which automatically reconstitute a drug, such as e.g., a lyophilized drug. A vial (30) containing the drug is fluidly coupled to a cartridge (12) containing a reconstitution liquid with a fluid conduit (14f), wherein an entry point is defined where the fluid conduit enters the vial (30). The device (10) automatically adjusts orientation of the vial (30) such that the entry point of the vial is gravitationally higher than the drug in the vial (30), and automatically transfers the reconstitution liquid out of the cartridge (12) and into the vial (30) to create a reconstituted drug. The device (10) also automatically adjusts the orientation of the vial (30) such that the entry point of the vial is gravitationally lower than the reconstituted drug, and automatically transfers the reconstituted drug from the vial (30) and into the cartridge (12).

Abstract: A device for automatically delivering a drug to a user and method thereof are disclosed. The device (10, 20, 70, 110) provides a connector to which a vial (12, 50, 60, 100, 130, 202) containing the drug is removably connected and situated thereto in a substantially inverted position. When commanded by the user, the device (10, 20, 70, 110) starts a reconstitution process to automatically create a reconstituted drug, and provides an indication that the reconstitution process is complete such that the vial (12, 50, 60, 100, 130, 202) may be removed from the connector (22, 72,112). After disposing the device (10, 20, 70, 110) on the user, the device (10, 20, 70, 110) can automatically deliver the reconstituted drug to the user when further commanded by the user.

Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.

Abstract: The present invention relates to polypeptide formulations with reduced viscosity and methods of making and using polypeptide formulations with reduced viscosity.

Abstract: Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate.

Abstract: Oligonucleotides for genotyping the thymidylate synthase gene are provided. The number of tandem repeats in the promoter region of the thymidylate synthase gene can be identified based on the hybridization of an oligonucleotide of the invention to the genomic DNA of a subject. Therefore, the genotype of the thymidylate synthase gene can be identified based on the number of tandem repeats. The genotype relates to the responsiveness of a subject towards an antitumor agent.

Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof.

Abstract: The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”).

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract: Methods and devices for conducting platelet aggregation analysis. A method for conducting platelet aggregation analysis by a cartridge device, including providing a blood sample in the cartridge device, stirring the blood sample within the cartridge device, measuring the electrical impedance between electrodes to obtain measured electrical impedance values, comparing measured electrical impedance values, discarding and repeating the measurements of the electrical impedance in case a variation of the measurements is outside a predetermined threshold range, or reporting the measured electrical impedance values in case the variation of the measurements is within the predetermined threshold range. Reported measured electrical impedance values indicate platelet aggregation in a blood sample.

Abstract: The invention provides shuttle agents and methods of using the same to facilitate the translocation of therapeutic or diagnostic molecules into the CNS.